Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 67 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/28/2008 First Published: 4/1/1999


1.		Phase III Randomized Study of Hyperthermic Isolated Limb Perfusion With Melphalan With or Without Tumor Necrosis Factor in Patients With Locally Advanced Extremity Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				ACOSOG-Z0020 NCI-03-C-0137, NCT00003789, ACOSOGZ0020

Last Modified: 1/1/2001


2.		Phase III Randomized Study of Hyperthermic Isolated Limb Perfusion with L-PAM vs L-PAM/TNF/IFN-G in Patients with Stage IIIA/IIIAB Malignant Melanoma Confined to an Extremity

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				UPCC-3695 NCI-92-C-0105H, NCI-T91-0238D, T91-0238


3.		Phase I/II Immunotherapy with rTNF in Patients with Metastatic Renal Cell Carcinoma and Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to physiologic 70								GENENTECH-MDA-86049 NCI-V86-0137

Last Modified: 1/1/1989


4.		Phase I/II Trial of Intravesical Recombinant Human Tumor Necrosis Factor in Patients with Superficial Bladder Carcinoma or Carcinoma in Situ of the Bladder (Summary Last Modified 01/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								NYU-8803 NCI-V88-0544

Last Modified: 8/1/1993


5.		Phase I/II Study of In Vivo-Primed TIL in Combination with IFN-A/IL-2 in Patients with Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over								UCLA-9102071 UCLA-UO-91-1, NCI-B91-0006, B91-0006

Last Modified: 9/1/1997


6.		Phase I/II Study of Hyperthermic Isolated Hepatic Perfusion With Tumor Necrosis Factor (TNF) and Melphalan (L-PAM) for Primary or Metastatic Hepatic Cancer (Summary Last Modified 09/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-93-C-0105M NCI-T94-0129N, T94-0129

Last Modified: 3/1/1994


7.		Phase II Study of Hyperthermic Isolated Limb Perfusion with TNF/L-PAM/IFN-G and Postoperative Systemic IL-2 in Patients with Stages IIIAB/IV Melanoma (Summary Last Modified 03/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over								NCI-94-C-0053A

Last Modified: 2/1/2002 First Published: 11/1/1999


8.		Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients with Unresectable High Grade Soft Tissue Sarcomas of the Extremity

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				15 and over				NCI				NCI-99-C-0145 NCI-T99-0067, NCT00019968

Last Modified: 9/1/1988


9.		Phase II Study of Recombinant Tumor Necrosis Factor in Patients with Low-Grade Lymphoma (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				LAC-USC-13NHL871 NCI-T87-0144D, T87-0144

Last Modified: 6/1/1989


10.		Phase II Study of rTNF in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 06/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age				NCI				CAN-NCIC-IND38 NCI-T87-0291O, T87-0291, IND38

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute